JP2008503476A5 - - Google Patents

Info

Publication number

JP2008503476A5

JP2008503476A5 JP2007516733A JP2007516733A JP2008503476A5 JP 2008503476 A5 JP2008503476 A5 JP 2008503476A5 JP 2007516733 A JP2007516733 A JP 2007516733A JP 2007516733 A JP2007516733 A JP 2007516733A JP 2008503476 A5 JP2008503476 A5 JP 2008503476A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

cancer

composition according

her2

her2 antibody

Prior art date

2005-06-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 36
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 24
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 24
• 239000002246 antineoplastic agent Substances 0.000 claims 13
• 229940127089 cytotoxic agent Drugs 0.000 claims 13
• 230000000340 anti-metabolite Effects 0.000 claims 10
• 229940100197 antimetabolite Drugs 0.000 claims 10
• 239000002256 antimetabolite Substances 0.000 claims 10
• 206010028980 Neoplasm Diseases 0.000 claims 9
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
• 201000011510 cancer Diseases 0.000 claims 7
• 229960005277 gemcitabine Drugs 0.000 claims 5
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 5
• 238000000034 method Methods 0.000 claims 5
• 201000001342 Fallopian tube cancer Diseases 0.000 claims 4
• 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 4
• 206010033128 Ovarian cancer Diseases 0.000 claims 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 4
• 229910052697 platinum Inorganic materials 0.000 claims 4
• 238000006243 chemical reaction Methods 0.000 claims 3
• 208000016691 refractory malignant neoplasm Diseases 0.000 claims 3
• 230000004083 survival effect Effects 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 2
• 239000000654 additive Substances 0.000 claims 2
• 230000000996 additive effect Effects 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 230000002195 synergetic effect Effects 0.000 claims 2
• NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 claims 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
• 108700011582 TER 286 Proteins 0.000 claims 1
• 229940123237 Taxane Drugs 0.000 claims 1
• 229940122803 Vinca alkaloid Drugs 0.000 claims 1
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 229950000772 canfosfamide Drugs 0.000 claims 1
• 229960004117 capecitabine Drugs 0.000 claims 1
• 238000006471 dimerization reaction Methods 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
• 239000000833 heterodimer Substances 0.000 claims 1
• 238000005734 heterodimerization reaction Methods 0.000 claims 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
• 229960005079 pemetrexed Drugs 0.000 claims 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
• 229960002087 pertuzumab Drugs 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 229960000303 topotecan Drugs 0.000 claims 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
• 229960000575 trastuzumab Drugs 0.000 claims 1
• -1 vinca alkaloids Chemical compound 0.000 claims 1